GALT - GALECTIN THERAPEUTICS INC
IEX Last Trade
0.9171
0.087 9.486%
Share volume: 10
Last Updated: Thu 26 Dec 2024 03:29:41 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$0.83
0.09
10.48%
Fundamental analysis
25%
Profitability
25%
Dept financing
3%
Liquidity
50%
Performance
25%
Performance
5 Days
-19.17%
1 Month
-68.98%
3 Months
-68.04%
6 Months
-62.30%
1 Year
-52.51%
2 Year
-31.10%
Key data
Stock price
$0.92
DAY RANGE
$0.83 - $0.83
52 WEEK RANGE
$0.88 - $4.27
52 WEEK CHANGE
-$49.66
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Joel Lewis
Region: US
Website: galectintherapeutics.com
Employees: 9
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: galectintherapeutics.com
Employees: 9
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Galectin Therapeutics Inc. engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer. Belapectins is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis.
Recent news